Phio Pharmaceuticals Corp. (NASDAQ: PHIO)
$4.88
+0.2100 ( +4.50% ) 17.0K
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
Market Data
Open
$4.88
Previous close
$4.67
Volume
17.0K
Market cap
$2.32M
Day range
$4.24 - $4.82
52 week range
$4.24 - $29.07
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 17 | Dec 08, 2023 |
10-q | Quarterly Reports | 52 | Nov 09, 2023 |
8-k | 8K-related | 15 | Nov 09, 2023 |
4 | Insider transactions | 1 | Oct 03, 2023 |
8-k | 8K-related | 14 | Aug 21, 2023 |
8-k | 8K-related | 14 | Aug 10, 2023 |
10-q | Quarterly Reports | 51 | Aug 10, 2023 |
8-k | 8K-related | 13 | Jul 26, 2023 |
4 | Insider transactions | 1 | Jul 05, 2023 |